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sial, and the safety and clinical value of HR combined with antiviral therapy for hepatitis B vi-
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Methods: We retrospectively evaluated 126 patients with BCLC stage B/C HCC who underwent
HR. These patients were divided into the antiviral group (Group A, n Z 86) and the control
group (Group B, n Z 40). The operative indications and prognosis of 126 patients were
analyzed.
Results: The 1-year, 3-year, and 5-year disease-free survival (DFS) rates for Group A and Group
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respectively. The DFS and OS for Group A were better than for Group B (p Z 0.013, and
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nd/4.0/).1. Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
malignancy in the world, and its incidence is increasing in
some countries.1,2 In the past few decades, although
several novel treatment options have been applied in the
clinical practice, curative hepatic resection (HR) pre-
dominates in the treatment for HCC. However, the prog-
nosis of HCC patients is discouraging, largely due to a high
incidence of intrahepatic recurrence.
According to the Barcelona Clinic Liver Cancer (BCLC)
staging system, HR is recognized as a first-line treatment for
patients who have well-preserved liver function and HCC
satisfying the BCLC A stage.3 In such patients, the 5-year
survival rate after HR remains > 50%.4e7 Recently, a large-
scale multicenter retrospective study demonstrated that HR
is a safeandeffective treatment forHCCoutsideBCLCAstage.
HR can provide a survival benefit over transarterial chemo-
embolization (TACE) for patients with BCLC B/C stage HCC on
condition that such patients have good liver function.8
In most Asia-Pacific countries, 75e80% of HCC are
related to chronic hepatitis B virus (HBV) infection. In a
retrospective study, researchers showed that antiviral
therapy effectively improved safety for HBV-related large
HCC patients who underwent major hepatectomy.9
Furthermore, ample evidence indicates that continuous
treatment with nucleos(t)ide analogues (NAs) in HBV-
related HCC patients after HR reduces the risk of HCC
recurrence and significantly improves overall survival
(OS).10,11 In China, the Chinese Medical Association rec-
ommends that NAs should be applied to HBV-related HCC
patients with detectable levels of HBV DNA, regardless of
alanine aminotransferase levels.12 Nevertheless, there is
little study of whether HR combined with antiviral therapy
can reduce postoperative recurrence and improve long-
term survival for patients with BCLC B/C stage HCC.
In this retrospective study, we described the clinical and
pathologic data of patients with BCLC B/C stage HCC, and
compared the therapeutic value of HR with the combina-
tion therapy of HR plus antiviral treatment.
2. Patients and methods
This study was approved by the ethics committees of the
third affiliated hospital of Sun Yat-Sen University, and it was
conducted in accordance with the Declaration of Helsinki.
2.1. Patients
In this retrospective study, a total of 283 patients were
identified who were diagnosed with HBV-related HCC andei Q, et al., Better prognosis of h
Stage B/C, Asian Journal of Surgunderwent HR between January 2006 and March 2010 at the
Department of Hepatic Surgery, The Third Affiliated Hos-
pital of Sun Yat-Sen University, China. The diagnosis of HCC
was based on histopathological study of the resected
specimens. All intraoperative and postoperative complica-
tions were recorded retrospectively.
2.2. Preoperative investigations
All patients were examined with preoperative evaluation
protocol, including chest radiography, ultrasonography of
the abdomen, contrast enhanced computed tomography or
magnetic resonance imaging of the abdomen, and laboratory
blood tests. The serum HBV-deoxyribonucleic acid (HBV-
DNA) levels were detected using the real-time polymerase
chain reaction (PCR) method (HBV PCR Kit, Da An Gene Co.,
Ltd. of Sun Yat-SenUniversity, Guangzhou, China). The lower
limit of detectionwas 100 IU/mL. The preoperative diagnosis
of HCC was based on the diagnostic criteria for HCC used by
the European Association for the Study of the Liver (EASL).13
2.3. Surgical procedure
In our study, HR should not be carried out in patients with a
small liver remnant or severe cirrhosis and with Child-Pugh C
liver function. A bilateral subcostal incision was used. Intra-
operative ultrasonography routinely was used to assess
resectabilityof the tumor, and toassess the relationshipof the
tumor to vascular structures. Pringlemaneuverwas applied to
occlude the blood inflow of the liver. Liver parenchymal
transection was performed with the clamp-crushing method.
Curative resection was defined as the removal of the entire
tumor with a histologically proved tumor-free surgical margin
and no tumor thrombus in themajor branches of the veins and
bile duct. Liver resection as potentially curative therapy was
performed in selectedpatients in BCLC stageB/C, aswell as in
patients with portal hypertension (PHT).
2.4. Inclusion criteria
Patients who met all of the following criteria were included
in the study: (1) positive test for hepatitis B surface antigen
and negative test for antibodies to hepatitis C; (2) HBV-DNA
level > 100 IU/mL; (3) BCLC B or C; (4) no lymph nodes and/
or distant metastasis; (5) no previous treatment of HCC; (6)
no previous history of antiviral therapy; and (7) detailed
and precise follow-up records.
In this study, the 147 consecutive HCC cases that
received HR were classified into two groups according to
whether or not they used antiviral therapy to treat hepa-
titis B-related BCLC B/C stage HCC. Patients in Group Aepatic resection combined with antiviral therapy for HBV-related
ery (2016), http://dx.doi.org/10.1016/j.asjsur.2016.03.001
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those in Group B (n Z 40) did not receive antiviral
treatment.
2.5. BCLC stage B/C, tumor node metastasis (TNM)
staging, and PHT
BCLC Stage B, multinodular, Eastern Cooperative Oncology
Group (ECOG)-0andChild-PughClassAorB.BCLCStageC,any
tumorwith radiologicallyevidentand/orhistologicallyproven
portal invasion, ECOG-1-2 and ChildePugh class A or B.14
In clinical practice, some surgeons have observed that
there is 1 subtype of HCC, solitary large HCC (SLHCC).15 This
type of HCC typically has just a solitary node, > 5 cm in
diameter, and grows expansively within an intact capsule or
pseudocapsule. According to the BCLC classification staging
system, SLHCC belongs to BCLC A or C stage.
Classification of the BCLC B/C stage HCC was made using
the sixth edition of the TNM classification of primary liver
tumorsof theUnion for International CancerControl (UICC).16
PHT was defined as the presence of esophageal varices
and/or a platelet count < 100  109/L in association with
splenomegaly.9
2.6. Treatment and follow-up
Patients in the antiviral group received adefovir at a dosage
of 10 mg/day, entecavir at a dosage of 0.5 mg/day, or
lamivudine at a dosage of 100 mg/day was recommended to
these patients once they had left the hospital or starting
from the first week after the operation, according to the
Chronic Hepatitis B Practice Guideline of the American As-
sociation for the Study of Liver Disease, the EASL.17,18 Those
in the control group did not receive any antiviral treatment.
Persistently undetectable HBV-DNA was defined as unde-
tectable HBV-DNA on two or more consecutive occasions, and
the assays were carried out at least 3 months apart. HBV
reactivation was defined as an increase in HBV-DNA level
greater than 10-fold compared with the baseline level for pa-
tients with detectable viral load or HBV-DNA level of> 100 IU/
mL for patients with undetectable viral load during follow-up.
Serum alpha-fetoprotein (AFP), ultrasonography or
computed tomography, and chest radiography were per-
formed every 3 months in the 1st postoperative year and
every 6 months in subsequent years. Recurrence during
follow-up was defined as the appearance of a new lesion
with radiologic features characteristic of HCC.
HCC patients with recurrence received hepatectomy,
radiofrequency ablation (RFA), TACE, sorafenib, or
cytokine-induced killer treatment. In Group A, the first
treatments against recurrence were TACE, RFA, and
repeated resection in 31, 17, and 18 patients, respectively.
However, the first treatments against recurrence in Group B
were TACE, RFA, and repeated resection in 17, four, and
one patients, respectively.
2.7. Statistical analysis
All demographic and clinicopathological data had been pro-
spectively collected in computer databases before this
retrospective analysis. Continuous variables were expressedPlease cite this article in press as: Wei Q, et al., Better prognosis of h
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the number and percentage. Differences between contin-
uous data were analyzed using the Mann-Whitney test. Dif-
ferences between categorical data were analyzed using the
c2 and Fisher exact tests. The OS and disease-free survival
(DFS) were estimated using the Kaplan-Meier method and
compared using the Log-rank test. Multivariate analysis was
carried out using the Cox proportional hazards model to
generate adjusted hazard ratios (HRs) and 95% confidence
intervals (CIs). SPSS 17.0 statistical package (SPSS, Inc.,
Chicago, IL, USA) was used for the statistical analyses. All
reported p values were those of two-sided tests. The statis-
tical significance was set at p < 0.05.
3. Results
3.1. Clinical and pathologic characteristics
From January 2006 and March 2010, 283 patients who un-
derwent HR for hepatitis B-related HCC were enrolled in
the prospective databases. On the basis of the inclusion
criteria, 126 patients (44.5%) were enrolled in this retro-
spective study (Figure 1).
Baseline demographic and clinicopathological data for
the 126 patients are shown in Table 1. No significant dif-
ferences were observed in age, sex, hepatitis B e antigen
(HBeAg) positivity, preoperative HBV-DNA level, serum AFP
or albumin level, tumor size, tumor nodule number, satel-
lite nodules, tumor capsule, macrovascular invasion, Child-
Pugh score, BCLC stage B/C, or PHT (all p > 0.05). However,
the level of creatinine differed significantly between Group
A and Group B (p Z 0.011).
3.2. HBV virological assessment
Patients in Group A received nucleoside analogues (lam-
ivudine or entecavir) or nucleotide analogues (adefovir)
treatment. The cumulative rates of undetectable HBV-DNA
(HBV-DNA < 100 IU/mL) at Week 12, Week 24, and Week 48
after HR were 26.5%, 50.6%, and 86.7%, respectively. The
rate of HBV reactivation in Group A was lower than that of
patients who did not receive antiviral treatment (4.7% vs.
25.6%, p Z 0.001).
3.3. Preoperative and postoperative data
Intraoperative and postoperative data are depicted in
Table 2; there were no significant differences in the pa-
rameters between the two groups. The overall hospital
mortality was 3.1% (4/126) after HR of the entire cohort of
HCC patients. There were three hospital deaths in Group A
and one death in Group B. The hospital deaths were
because of two cases of liver failure, one cardiac failure/
arrhythmia, and one peptic ulcer bleeding.
3.4. OS and DFS
The comparison of OS and DFS between patients undergoing
HR combined with antiviral treatment and HR is shown in
Figure 2. During a follow-up period lasting a median ofepatic resection combined with antiviral therapy for HBV-related
ry (2016), http://dx.doi.org/10.1016/j.asjsur.2016.03.001
Figure 1 Flowchart of the patient selection process. BCLC Z Barcelona Clinic Liver Cancer; HBV Z hepatitis B virus;
HCV Z hepatitis C virus.
Table 1 Clinicopathologic characteristics of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients with
Barcelona Clinic Liver Cancer (BCLC) stage B/C who received hepatic resection (HR) or HR plus antiviral therapy.
Variables Group A (n Z 86) Group B (n Z 40) p
Age (y) 50.8  10.5 50.0  13.8 0.702
Gender, M/F, n (%) 79 (91.9)/7 (8.1) 35 (87.5)/5 (12.5) 0.438
HBeAg positivity, n (%) 14 (16.3) 6 (15.0) 0.855
Preoperative HBV-DNA level (log10 IU/mL) 6.9 (2.0e8.8) 5.7 (2.0e6.7) 0.440
Preoperative laboratory test
Hemoglobin (g/L) 137.3  17.0 134.6  19.1 0.424
Platelet count (109/L) 193.5  74.6 205.5  78.6 0.412
Prothrombin times, (s) 13.3  1.4 13.3  1.0 0.987
Bilirubin (mmol/L) 17.3  15.6 15.0  7.8 0.371
Albumin (g/L) 39.2  3.6 39.4  4.7 0.812
Alanine aminotransferase (IU/L) 47.8  32.2 49.5  33.2 0.536
Creatinine (mmol/L) 75.4  13.4 68.8  13.7 0.011
Serum AFP < 400 ng/mL /  400 ng/mL, n (%) 44 (54.0)/42 (46.0) 16 (40.0)/24 (60.0) 0.243
Tumor characteristics
Tumor size (cm) 8.0 (1.5e25.0) 8.9 (3.0e18.8) 0.135
Tumor nodule number solitary/multiple, n (%) 27 (31.4)/59 (68.6) 15 (37.5)/25 (62.5) 0.499
Satellite nodules, n (%) 31 (36.0) 14 (35.0) 0.909
Capsule, n (%) 40 (46.0) 19 (47.5) 0.918
Macrovascular invasion, n (%) 38 (44.2) 18 (45.0) 0.932
Liver cirrhosis, n (%) 73 (84.9) 36 (90.0) 0.434
Child-Pugh score A/B, n (%) 82 (95.3)/4 (4.7) 39 (97.5)/1 (2.5) 0.565
TNM stage II/III, n (%) 36 (41.9)/50 (58.1) 15 (37.5)/25 (62.5) 0.643
BCLC stage B/C, n (%) 48 (55.8)/38 (44.2) 22 (55.0)/18 (45.0) 0.932
PHT, n (%) 28 (32.5) 9 (22.5) 0.249
AFPZ alpha-fetoprotein; BCLCZ Barcelona Clinic Liver Cancer; HBeAgZ hepatitis B e antigen; HBVZ hepatitis B virus; PHTZ portal
hypertension.
Continuous data are expressed as mean  SD.
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Table 2 Intraoperative and postoperative data.
Data Group A
(n Z 86)
Group B
(n Z 40)
p
Operative time (min) 219.4  101.7 210.45  88.2 0.362
Clamp time (min) 25.0  6.1 28.6  6.2 0.336
Intraoperative blood
loss (mL)
399.4  337.3 402.5  367.9 0.968
Surgical margin (cm), n (%)
 1.0 21 (24.4) 12 (27.7) 0.520
> 1.0 65 (75.5) 28 (72.3)
Blood transfusion, n (%)
Yes 22 (25.6) 10 (25.0) 0.944
No 64 (74.4) 30 (75.0)
Hospital stay (d) 28.3  13.7 29.6  15.2 0.624
Infectious complications, n (%)
Wound infection 2 (2.3) 0 (0.0) 0.331
Pulmonary infection 2 (2.3) 1 (2.5) 0.952
Abdomen infection 4 (4.7) 2 (5.0) 0.932
Noninfectious complications, n (%)
Peptic ulcer bleeding 1 (1.2)/1* 0 (0.0) 0.494
Pleural effusion 4 (4.7) 1 (2.5) 0.565
Biliary fistula 1 (1.2) 0 (0.0) 0.494
Liver failure 1 (1.2)/1* 1 (2.5)/1* 0.576
Cardiac failure/
arrhythmia
1 (1.2)/1* 0 (0.0) 0.494
Hospital deaths 3 (3.5)* 1 (2.5)* 0.768
Continuous data are expressed as mean  SD.
*Hospital death was defined as death during the hospital stay
after operative (within 30 days).
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patients who received antiviral therapy were significantly
better than for those who did not receive antiviral therapy
(pZ 0.038, pZ 0.013). The 1-, 3-, and 5-year OS rates forFigure 2 The cumulative overall survival (A) and disease-free s
related hepatocellular carcinoma (HCC) patients treated with hep
Please cite this article in press as: Wei Q, et al., Better prognosis of h
hepatocellular carcinoma with BCLC Stage B/C, Asian Journal of Surgethe antiviral group and the nonantiviral group were 89.2%,
61.4%, 45.8% and 82.1%, 48.7%, 33.3%, respectively. The 1-,
3-, 5-year DFS rates for the antiviral group and the non-
antiviral group were 55.4%, 36.1%, 33.7% and 53.8%, 28.2%,
23.1%, respectively.
Univariate analysis revealed that preoperative HBV-DNA
level, AFP level, tumor size, tumor nodule number, tumor
capsule, macroscopic vascular invasion, surgical margin,
TNM staging, and antiviral treatment were all significantly
associated with OS. However, on multivariate analysis,
there only four significant factors were associated with
poor postoperative OS: HBV-DNA level > 20,000 IU/mL
(p Z 0.001, HR Z 3.465, 95% CI: 1.719e6.984), macro-
scopic vascular invasion (p Z 0.016, HR Z 2.156, 95% CI:
1.323e5.132), TNM III (p Z 0.010, HR Z 2.825, 95% CI:
1.284e6.250), and surgical margin  1.0 cm (p Z 0.019,
HR Z 2.329, 95% CI: 1.673e5.137). Antiviral treatment
(p Z 0.014, HR Z 0.409, 95% CI: 0.200e0.837) was a sig-
nificant protective factor of OS (Table 3).
Among 122 patients, 69 developed early HCC recurrences
within 2 years of HR. Multivariate analysis showed that tumor
size  10 cm, macroscopic vascular invasion, blood trans-
fusion, surgicalmargin1.0 cmandTNM IIIwere significantly
associated with early tumor recurrence. Antiviral treatment
was not associated with a low risk of early tumor recurrence.
However, on multivariate analysis of the risk variables asso-
ciated with late recurrence in the remaining 53 patients,
antiviral treatment (p Z 0.011, HR Z 0.391, 95%CI:
0.190e0.806) was an independent protective factor of late
tumor recurrence (Table 4).3.5. Subgroup analysis by preoperative HBV-DNA
level
In subgroup analysis by preoperative HBV-DNA level, pa-
tients in each group were divided into subgroups withurvival (B) of Group A and Group B of hepatitis B virus (HBV)-
atic resection (HR).
epatic resection combined with antiviral therapy for HBV-related
ry (2016), http://dx.doi.org/10.1016/j.asjsur.2016.03.001
Table 3 Variables in Cox regression univariate and multivariate analysis of overall survival of hepatitis B virus (HBV)-related
hepatocellular carcinoma (HCC) patients who underwent hepatic resection (HR).
Variables Univariate analysis Multivariate analysis
HR 95% CI p HR 95% CI p
Gender (M/F) 1.222 0.483e3.092 0.672
Age (> 60 y /  60 y) 1.001 0.498e2.011 0.998
HBeAg positivity (Y/N) 1.209 0.557e2.620 0.631
HBV-DNA level (> 200,000 IU/mL /  200,000 IU/mL) 2.696 1.418e5.128 0.002 3.465 1.719e6.984 0.001
AFP ( 400 ng/mL / < 400 ng/mL) 1.548 0.860e2.783 0.045
Platelet count ( 100  109/L / > 100  109/L) 1.686 0.407e6.993 0.472
Prothrombin times ( 13 s / < 13 s) 1.107 0.631e1.946 0.721
TBIL ( 17 mmol/L / < 17 mmol/L) 1.302 0.705e2.404 0.398
Albumin (< 35 g/L /  35 g/L) 2.222 0.901e5.464 0.083
Alanine aminotransferase ( 40 IU/L / < 40 IU/L) 1.344 0.741e2.438 0.330
Liver cirrhosis (Y/N) 1.220 0.603e2.469 0.702
Tumor size ( 10 cm / < 10 cm) 2.039 1.139e3.649 0.017
Tumor nodule number (multiple/solitary) 2.320 1.258e4.274 0.007
Satellite nodules (Y/N) 1.572 0.845e2.924 0.154
Capsule (N/Y) 2.149 1.194e3.868 0.011
Macroscopic vascular invasion (Y/N) 1.585 0.880e2.856 0.005 2.156 1.323e5.132 0.016
PHT (Y/N) 1.010 0.532e1.919 0.975
Clamp time (> 30 min /  30 min) 1.018 0.976e1.062 0.405
Operation time (>180 min /  180 min) 1.072 0.608e1.890 0.809
Blood loss (> 1000 mL /  1000 mL) 2.118 0.655e6.853 0.210
Blood transfusion (Y/N) 2.366 0.726e7.714 0.153
Surgical margin ( 1.0 cm / > 1.0 cm) 1.782 1.113e3.401 0.018 2.329 1.673e5.137 0.019
TNM stage (III/II) 2.016 1.147e3.546 0.015 2.825 1.284e6.250 0.010
Antiviral treatment (Y/N) 0.334 0.177e0.629 0.001 0.409 0.200e0.837 0.014
CI Z confidence interval; HBV Z hepatitis B virus; PHT Z portal hypertension; TBIL Z total bilirubin.
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than 200,000 IU/mL (n Z 93). Compared to nonantiviral
group patients with lower HBV-DNA level (< 200,000 IU/mL),
antiviral treatment provided better long-term survival
(pZ 0.008, Figure 3A). The antiviral therapy group showed a
survival benefit at 1 year (92.2% vs. 86.2%), 3 years (67.2% vs.
51.7%), and 5 years (53.1% vs. 41.3%). Similarly, among pa-
tientswithhigherHBV-DNA level (200,000 IU/mL), antiviral
treatment provided better long-term survival (p Z 0.020,
Figure 3B). Antiviral treatment showed a survival benefit at
1 year (84.2% vs. 70.0%) and 3 years (63.1% vs. 30.0%).Table 4 Multivariate analysis of clinicopathological factors pre
noma (HCC) patients who underwent hepatic resection (HR).
Variables Early recu
HR 95% CI
Tumor size ( 10 cm / < 10 cm) 2.794 1.385e
Macroscopic vascular invasion (Y/N) 1.795 1.019e
Blood transfusion (Y/N) 1.458 1.008e
Surgical margin ( 1.0 cm / > 1.0 cm) 2.004 1.021e
TNM stage (III/II) 2.358 1.092e
Antiviral treatment (Y/N)
CI Z confidence interval; HR Z hepatic resection.
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Patients were stratified on the basis of the absence of
macrovascular invasion (BCLC-B) or on its presence (BCLC-
C). In HCC patients of BCLC Stage B (n Z 66), the antiviral
group was identified to achieve significant survival
improvement with NAs compared to the nonantiviral group
(p Z 0.022, Figure 3C). Antiviral treatment showed a sur-
vival benefit at 1 year (91.1% vs. 81.0%), 3 years (64.4% vs.
52.4%), and 5 years (51.1% vs. 38.1%). However, there was
no statistically significant difference between OS of thedictive of early and late recurrence of hepatocellular carci-
rrence Late recurrence
p HR 95% CI p
5.453 0.004 2.674 1.337e5.348 0.005
3.431 0.027
2.841 0.018
3.922 0.043
5.102 0.029 2.950 1.344e6.452 0.007
0.391 0.190e0.806 0.011
epatic resection combined with antiviral therapy for HBV-related
ery (2016), http://dx.doi.org/10.1016/j.asjsur.2016.03.001
Figure 3 Overall survival curves of subgroups of patients with Barcelona Clinic Liver Cancer (BCLC) stage B/C hepatocellular
carcinoma (HCC) who received hepatic resection (HR) combined with antiviral treatment or HR. Subgroups were defined (A)
preoperative hepatitis B virus (HBV)-DNA level < 200,000 IU/mL, (B) preoperative HBV-DNA level  200,000 IU/mL, (C) BCLC stage
B, and (D) BCLC stage C.
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of BCLC Stage C (n Z 56) (p Z 0.055, Figure 3D).
3.7. Subgroup analysis by pathological type
Patients receiving each kind of treatment were divided into
SLHCC and nodular HCC (NHCC) subgroups with pathological
type. In SLHCC HCC patients (n Z 41), the antiviral group
was identified to achieve significant survival improvement
with NAs compared to the nonantiviral group (p Z 0.033,
Figure 4A). Antiviral treatment showed a survival benefit at
1 year (92.6% vs. 85.7%), 3 years (81.5% vs.64.3%), andPlease cite this article in press as: Wei Q, et al., Better prognosis of h
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(n Z 81), OS was better for the antiviral group than the
nonantiviral group (1 year, 87.5% vs. 72.0%; 3 years, 48.2%
vs. 32.0%; 5 years, 39.2% vs. 24.0%; pZ 0.013) (Figure 4A).
Compared to antiviral group in NHCC patients, antiviral
treatment in SLHCC patients provided better long-term
survival (p Z 0.001, Figure 4A).
3.8. Subgroup analysis by TNM staging
A total of 83 patients receiving antiviral treatment were
divided into TNM II and III subgroups according to UICC-TNMepatic resection combined with antiviral therapy for HBV-related
ry (2016), http://dx.doi.org/10.1016/j.asjsur.2016.03.001
Figure 4 Overall survival of antiviral group in subgroup analysis stratified by (A) pathological type and (B) TNM staging.
NHCC Z nodular hepatocellular carcinoma; SLHCC Z solitary large hepatocellular carcinoma.
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OS between TNM II and TNM III patients (p Z 0.035,
Figure 4B).4. Discussion
According to BCLC classification, HR is not recommended as
the first-line treatment for HCC patients with BCLC B/C
stage.19,20 However, some selected HCC patients with BCLC
B/C stage have received HR in real clinical practice. Some
retrospective clinical studies showed that HR is a safe and
effective treatment as long as preoperative liver function
and the size of liver remnant volume are adequate; espe-
cially HR should not be determined solely by the presence
or absence of macrovascular invasion in HCC.8,15,21 In our
retrospective cohort, the rate of postoperative complica-
tions and perioperative mortality in these HCC patients was
16.7% and 3.1%, respectively. Our results also suggest that
HR performed carefully on selected patients is a safe
treatment for HCC patients with BCLC B/C stage.
While NAs are effective against primary HCC, studies on
whether antiviral therapy is useful in reducing post-
operative recurrence of HCC patients showed controversial
results.22e26 This study was designed to find whether HR
combined with NAs could improve OS and DFS in the setting
of HBV-related HCC. Fortunately, our study found differ-
ences in OS and DFS in these groups of patients. The ma-
jority of previous studies did not report the prognosis of
BCLC stage B/C HCC patients who received HR combined
with antiviral treatment. Only one study indicated that OS
in BCLC Stage C HCC patients after HR plus antiviral
treatment was 81.8% (1 year), 61.4% (3 years), and 43.8%
(5 years).27
In the present study, we indicate that antiviral therapy is
a strong protective factor for late tumor recurrence and OSPlease cite this article in press as: Wei Q, et al., Better prognosis of h
hepatocellular carcinoma with BCLC Stage B/C, Asian Journal of Surgafter HR. We speculated that antiviral therapy improves OS
in patients with BCLC B/C stage HBV-related HCC after HR
through three main mechanisms: suppressing HBV replica-
tion and reactivation; easing liver inflammation and
improving hepatic functional reserve; and indirectly pre-
venting late tumor recurrence. It has been reported that
hepatitis activity in the remnant liver is associated with
tumor recurrence after HR,28,29 especially in late recur-
rence.30 The interaction between tumor progression and
liver dysfunction reflects especially on advanced HCC pa-
tients.31 A high HBV viral load leads to active inflammation
in the remnant liver, and then causes tumor recurrence via
intrahepatic metastases from similarly differentiated main
tumors or multicentric carcinogenesis.32,33 Theoretically,
antiviral therapy may preserve the liver function, increase
residual liver volume after hepatectomy, and give BCLC B/C
stage HBV-related HCC patients a higher chance to receive
successful and aggressive salvage therapy during recur-
rence, resulting in a better survival. Kuzuya et al34 and Li
et al35 found that the increase (recovery) in residual liver
volume after HR was significantly greater in patients who
had received antiviral therapy than in the control group
patients, and this significantly enhanced tolerance to sub-
sequent therapy for prevention of HCC recurrence.
Furthermore, Wong et al36 showed that antiviral therapy
could significantly improve OS, as both the mortality
related to liver failure and the overall mortality were
reduced by 87% and 73%, respectively.
Our multivariate Cox modeling to identify prognostic
factors in BCLC B/C stage HCC patients came to similar
conclusions as previous studies: patients with high preop-
erative HBV-DNA level, large tumor size, macroscopic
vascular invasion, surgical margin  1.0 cm, TNM stage.11
Our study reported that preoperative serum HBV-DNA
levels  200,000 IU/mL was a strong risk predictor of OS.
Patients with higher level of HBV-DNA were more likely toepatic resection combined with antiviral therapy for HBV-related
ery (2016), http://dx.doi.org/10.1016/j.asjsur.2016.03.001
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endure survival disadvantages brought by liver dysfunction.
Patients with HBV-DNA levels  200,000 IU/mL could get
better potential survival benefit from antiviral therapy.
Our study suggests that adjuvant antiviral therapy did
not obtain obvious survival benefits in HBV-related HCC
patients with the BCLC C stage showing major vascular in-
vasion after hepatectomy. Our findings are supported by
previous studies.27,38 This may be attributed to the fact
that tumor factors dominate the prognoses tumor factors in
patients with advanced stage HCC, even after curative HR,
thereby diminishing the effect of antiviral therapy in
improving the “field factors” of the nontumor part.37,39 In
addition, BCLC C stage HCC patients treated with HR had
these pathological characteristics, which are susceptible to
HCC intrahepatic and extrahepatic metastases. Antiviral
therapy could not hinder this process.
SLHCC exhibits a similar incidence of metastasis and
long-time outcome with small HCC after hepatectomy.15
Whether HR combined antiviral treatment could achieve
significant survival improvement is unclear. Our study
further suggest the OS for the SLHCC patients who received
antiviral therapy was significantly better than that of NHCC
patients and the patients who did not receive antiviral
treatment. This could be attributed to the specific molec-
ular biologic characteristics of SLHCC that is associated
with better prognosis. It is regretful that we did not eval-
uate the effect of antiviral treatment in small HCC
patients.
While we interpret these findings to mean that antiviral
treatment suppresses HBV replication and reactivation,
easing liver inflammation and improving hepatic functional
reserve, we do emphasize the need for receiving lifelong
antiviral treatment, regardless of the level of HBV-DNA and
HBeAg seroconversion in HBeAg-positive patients or hepa-
titis B surface antigen loss in HBeAg-negative patients. In
our study, we examined the effect of entecavir and lam-
ivudine /þ adefovir on long-term outcome after HR. There
was no significant difference between the antiviral drugs.
These findings are partly consistent with some previous
studies.40,41 In China, according to expert consensus on
antiviral therapy for special patients with chronic hepatitis
B an update in 2015, entecavir or tenofovir as first-choice
antiviral drugs were recommended to HBV-related HCC
patients with detectable levels of HBV DNA.
Given the relatively small populations in our studies, and
their retrospective design, more Randomized Controlled
Trial (RCT) with large sample size and long-term follow-up
are warranted to prove our results. Furthermore, our study
had several limitations mainly because of the lack of
complete information, including the rate of the virus and
gene mutation, the HBV genotype, and evaluation of the
extent of HBV inflammation when HCC recurrence, but also
because of a retrospective analysis from one center.Acknowledgments
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